Healthcare Medical Devices Biotechnology

Bispecific Antibody Market Report Cover

Bispecific Antibody Market

Bispecific Antibody Market Report Cover

Bispecific Antibody Market Size, Share, Growth & Industry Analysis, By Indication (Cancer, Inflammatory & Autoimmune Disorder, Others), By Distribution Channel (Hospital, Retail, Drugstores, Online), and Regional Analysis, 2024-2031

Author : Swati J.


Pages : 120

Base Year : 2023

Release : August 2024

Report ID: KR977


TABLE OF CONTENT

1 INTRODUCTION OF THE GLOBAL BISPECIFIC ANTIBODY MARKET 
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Limitations
1.5 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 Data Collection
3.1.1 Secondary Sources
3.1.2 Primary Sources
3.1.3 Research Flow
3.2 Subject Matter Expert Advice
3.3 Quality Check
3.4 Final Review
3.5 Bottom-Up Approach
3.6 Top-down Approach

4 GLOBAL BISPECIFIC ANTIBODY MARKET OUTLOOK
4.1 Market Evolution
4.2 Overview
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.3.4 Challenges
4.4 Pricing Analysis
4.5 Porter’s Five Forces Analysis
4.6 Value Chain Analysis
4.7 Macroeconomic Analysis

5 IMPACT OF RUSSIA-UKRAINE WAR

6 GLOBAL BISPECIFIC ANTIBODY MARKET, BY INDICATION
6.1 Overview
6.2 Cancer
6.3 Inflammatory & Autoimmune Disorder
6.4 Others

7 GLOBAL BISPECIFIC ANTIBODY MARKET, BY DISTRIBUTION CHANNEL
7.1 Overview
7.2 Hospital 
7.3 Retail 
7.4 Drugstores
7.5 Online 

8 GLOBAL BISPECIFIC ANTIBODY MARKET, BY GEOGRAPHY
8.1 Overview

9 NORTH AMERICA 
9.1 U.S.
9.2 Canada
9.3 Mexico

10 EUROPE 
10.1 Germany
10.2 U.K.
10.3 France
10.4 Italy
10.5 Spain
10.6 Russia
10.7 Rest of Europe

11 ASIA-PACIFIC 
11.1 China
11.2 Japan
11.3 India
11.4 South Korea
11.5 Rest of Asia-Pacific

12 MIDDLE EAST & AFRICA 
12.1 GCC
12.2 South Africa
12.3 North Africa
12.4 Rest of Middle East & Africa

13 LATIN AMERICA 
13.1 Brazil
13.2 Argentina
13.3 Rest of South America

14 GLOBAL BISPECIFIC ANTIBODY MARKET COMPETITIVE LANDSCAPE
14.1 Overview
14.2 Key Developments
14.3 Key Strategic Developments
14.4 Company Market Ranking
14.5 Regional Footprint
14.6 Industry Footprint

15 COMPANY PROFILES
15.1 Genentech, Inc. 
15.1.1 Key Facts
15.1.2 Financial Overview
15.1.3 Product Benchmarking
15.1.4 Recent Developments
15.1.5 Winning Imperatives
15.1.6 Current Focus & Strategies
15.1.7 Threat from competition
15.1.8 SWOT Analysis
15.2 Amgen Inc.
15.2.1 Key Facts
15.2.2 Financial Overview
15.2.3 Product Benchmarking
15.2.4 Recent Developments
15.2.5 Winning Imperatives
15.2.6 Current Focus & Strategies
15.2.7 Threat from competition
15.2.8 SWOT Analysis
15.3  F. Hoffmann-La Roche Ltd  
15.3.1 Key Facts
15.3.2 Financial Overview
15.3.3 Product Benchmarking
15.3.4 Recent Developments
15.3.5 Winning Imperatives
15.3.6 Current Focus & Strategies
15.3.7 Threat from competition
15.3.8 SWOT Analysis
15.4 Novartis AG
15.4.1 Key Facts
15.4.2 Financial Overview
15.4.3 Product Benchmarking
15.4.4 Recent Developments
15.4.5 Winning Imperatives
15.4.6 Current Focus & Strategies
15.4.7 Threat from competition
15.4.8 SWOT Analysis
15.5 Regeneron Pharmaceuticals Inc.
15.5.1 Key Facts
15.5.2 Financial Overview
15.5.3 Product Benchmarking
15.5.4 Recent Developments
15.5.5 Winning Imperatives
15.5.6 Current Focus & Strategies
15.5.7 Threat from competition
15.5.8 SWOT Analysis
15.6 Sanofi S.A.
15.6.1 Key Facts
15.6.2 Financial Overview
15.6.3 Product Benchmarking
15.6.4 Recent Developments
15.6.5 Winning Imperatives
15.6.6 Current Focus & Strategies
15.6.7 Threat from competition
15.6.8 SWOT Analysis
15.7 Johnson & Johnson Services, Inc.
15.7.1 Key Facts
15.7.2 Financial Overview
15.7.3 Product Benchmarking
15.7.4 Recent Developments
15.7.5 Winning Imperatives
15.7.6 Current Focus & Strategies
15.7.7 Threat from competition
15.7.8 SWOT Analysis
15.8 Merck & Co., Inc.
15.8.1 Key Facts
15.8.2 Financial Overview
15.8.3 Product Benchmarking
15.8.4 Recent Developments
15.8.5 Winning Imperatives
15.8.6 Current Focus & Strategies
15.8.7 Threat from competition
15.8.8 SWOT Analysis
15.9 AbbVie Inc.
15.9.1 Key Facts
15.9.2 Financial Overview
15.9.3 Product Benchmarking
15.9.4 Recent Developments
15.9.5 Winning Imperatives
15.9.6 Current Focus & Strategies
15.9.7 Threat from competition
15.9.8 SWOT Analysis
15.10 Eli Lilly and Company
15.10.1 Key Facts
15.10.2 Financial Overview
15.10.3 Product Benchmarking
15.10.4 Recent Developments
15.10.5 Winning Imperatives
15.10.6 Current Focus & Strategies
15.10.7 Threat from competition
15.10.8 SWOT Analysis

LIST OF TABLES

TABLE 1 Global BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 2 Global BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 3 Global BISPECIFIC ANTIBODY MARKET Revenue, By Geography, 2021 – 2031 (USD Billion)
TABLE 4 North America BISPECIFIC ANTIBODY MARKET Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 5 North America BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 6 North America BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 7 US BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 8 US BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 9 Canada BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 10 Canada BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 11 Mexico BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 12 Mexico BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 13 Europe BISPECIFIC ANTIBODY MARKET Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 14 Europe BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 15 Europe BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 16 Germany BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 17 Germany BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 18 France BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 19 France BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 20 U.K. BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 21 U.K. BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 22 Spain BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 23 Spain BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 24 Italy BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 25 Italy BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 26 Russia BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 27 Russia BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 28 Rest of Europe BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 29 Rest of Europe BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 30 Asia-Pacific BISPECIFIC ANTIBODY MARKET Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 31 Asia-Pacific BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 32 Asia-Pacific BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 33 China BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 34 China BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 35 Japan BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 36 Japan BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 37 India BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 38 India BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 39 South Korea BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 40 South Korea BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 41 Rest of Asia-Pacific BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 42 Rest of Asia-Pacific BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 43 Middle East and Africa BISPECIFIC ANTIBODY MARKET Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 44 Middle East and Africa BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 45 Middle East and Africa BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 46 GCC BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 47 GCC BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 48 North Africa BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 49 North Africa BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 50 South Africa BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 51 South Africa BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 52 Rest of Middle East & Africa BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 53 Rest of Middle East & Africa BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 54 Latin America BISPECIFIC ANTIBODY MARKET Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 55 Latin America BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 56 Latin America BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 57 Brazil BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 58 Brazil BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 59 Argentina BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 60 Argentina BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 61 Rest of Latin America BISPECIFIC ANTIBODY MARKET Revenue, By Indication, 2021 – 2031 (USD Billion)
TABLE 62 Rest of Latin America BISPECIFIC ANTIBODY MARKET Revenue, By Distribution Channel, 2021 – 2031 (USD Billion)
TABLE 63 Company Market Ranking
TABLE 64 Regional Footprint
TABLE 65 Product Benchmarking
TABLE 66 Recent Developments
TABLE 67 Winning Imperatives 

LIST OF FIGURES

FIG. 1 Market Segmentation
FIG. 2 Research Timeline
FIG. 3 Global BISPECIFIC ANTIBODY MARKET 2021-2031 (USD Billion)
FIG. 4 Global BISPECIFIC ANTIBODY MARKET Geographical Analysis (CAGR %)
FIG. 5 Global Bispecific Antibodies Absolute Market Opportunity (USD Billion)
FIG. 6 Global BISPECIFIC ANTIBODY MARKET Attractiveness (USD Billion)
FIG. 7 Global BISPECIFIC ANTIBODY MARKET, By Indication, 2021-2031 (USD Billion)
FIG. 8 Global BISPECIFIC ANTIBODY MARKET, By Distribution Channel, 2021-2031 (USD Billion)
FIG. 9 Research Methodology
FIG. 10 Research Process
FIG. 11 Bottom-Up Approach
FIG. 12 Top-Bottom Approach
FIG. 13 Market Dynamics Overview
FIG. 14 Porter's Five Forces Analysis
FIG. 15 Value Chain Analysis
FIG. 16 Macroeconomic Analysis
FIG. 17 Global BISPECIFIC ANTIBODY MARKET Revenue Share, By Indication, 2023 and 2031 (%)
FIG. 18 Global BISPECIFIC ANTIBODY MARKET Revenue Share, By Distribution Channel, 2023 and 2031 (%)
FIG. 19 Global BISPECIFIC ANTIBODY MARKET Revenue Share, By Geographic Regions, 2023 and 2031 (%)
FIG. 20 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 21 North America BISPECIFIC ANTIBODY MARKET Overview Share, By Countries, 2021 – 2031 (%)
FIG. 22 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 23 Europe BISPECIFIC ANTIBODY MARKET Overview Share, By Countries, 2021 – 2031 (%)
FIG. 24 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 25 Asia-Pacific BISPECIFIC ANTIBODY MARKET Overview Share, By Countries, 2021 – 2031 (%)
FIG. 26 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 27 Middle East & Africa BISPECIFIC ANTIBODY MARKET Overview Share, By Countries, 2021 – 2031 (%)
FIG. 28 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 29 Latin America BISPECIFIC ANTIBODY MARKET Overview Share, By Countries, 2021 – 2031 (%)
FIG. 30 Key Strategic Development
FIG. 31 Key Facts
FIG. 32 Financial Overview
FIG. 33 SWOT Analysis

CHOOSE LICENCE TYPE

CUSTOMIZATION OFFERED

  • Check Icon Additional Company Profiles
  • Check Icon Additional Countries
  • Check Icon Cross Segment Analysis
  • Check Icon Regional Market Dynamics
  • Check Icon Country-Level Trend Analysis
  • Check Icon Competitive Landscape Customization
  • Check Icon Extended Forecast Years
  • Check Icon Historical Data Up to 5 Years
Global Bispecific Antibodies MarketSize, 2021-2031 (USD Billion)7.54 Bn66.23 Bn100%Chart created using amCharts library
Chart created using amCharts library
Chart created using amCharts library
Global Bispecific Antibodies MarketShare, By Indication, 2023 (%)Cancer: 75.0%Inflammatory & Autoimmune Disorder: 19.7%Others: 5.2%CancerInflammatory …Others100%Chart created using amCharts library
Chart created using amCharts library
Chart created using amCharts library
Middle East & AfricaAsia-PacificEuropeNorth AmericaLatin America100%Chart created using amCharts library
Zoom level changed to 1